Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook
November 1, 2016 4:15 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.23, $0.02 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $177.5 million versus the consensus estimate of $172.85 million.
GUIDANCE:
Myriad Genetics sees Q2 2017 EPS of $0.23-$0.25, versus the consensus of... More
